Sexual & Reproductive Medicine, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
J Sex Med. 2013 Jan;10(1):195-203. doi: 10.1111/j.1743-6109.2012.02885.x. Epub 2012 Sep 12.
Prostate cancer is common, and, thus, more men are being treated surgically. Long-term functional outcomes are of significant importance to the patient and their partners. Erectile function (EF) preservation (rehabilitation) has gained significant traction worldwide, despite the absence of definitive evidence supporting its use.
To review the effectiveness of specific pharmacological therapies and other erectogenic aids in the treatment of post-radical prostatectomy (RP) erectile dysfunction.
A systematic literature review of original peer-reviewed manuscripts and clinical trials reported in Medline.
This review focused on the evaluation of interventions that aimed to improve EF recovery following RP.
Although well documented in animal models, studies supporting the rehabilitation with phosphodiesterase type 5 inhibitors in humans are scarce. Daily sildenafil has been used in trials (only one randomized placebo-controlled trial) with a significant improvement in erection recovery when compared to placebo or no rehabilitation but with a low return to baseline rates (27% vs. 4% placebo). Nightly vardenafil vs. on demand vs. placebo has been studied in the Recovery of Erections: INtervention with Vardenafil Early Nightly Therapy trial with no difference in erection recovery following RP. Intracavernosal injections, although widely used and attractive from a rehabilitation standpoint, does not yet have definitive supporting its role in rehabilitation. Vacuum erection devices use following RP has been reported, but there are no data to support its role as monotherapy. Intraurethral alprostadil was also studied vs. sildenafil in a multicenter, randomized, open-label trial, and no superiority was found.
At this time, we are unable to define what represents the optimal rehabilitation program in regard to strategies utilized, timing of intervention, or duration of treatment.
前列腺癌很常见,因此有更多的男性接受手术治疗。长期的功能结果对患者及其伴侣非常重要。尽管缺乏支持其使用的明确证据,但全球范围内对保留(康复)勃起功能的兴趣日益浓厚。
综述特定药理学治疗方法和其他勃起辅助手段在根治性前列腺切除术后(RP)勃起功能障碍治疗中的有效性。
对 Medline 中原始同行评审文献和临床试验进行系统的文献复习。
本综述重点评估了旨在改善 RP 后 EF 恢复的干预措施。
尽管在动物模型中得到了很好的证明,但支持在人类中使用 5 型磷酸二酯酶抑制剂进行康复的研究却很少。在试验中,已使用每日西地那非(仅一项随机安慰剂对照试验),与安慰剂或无康复相比,勃起功能恢复有显著改善,但恢复至基线的比例较低(27%比安慰剂 4%)。在“REVIVE 试验:早期每晚给予伐地那非治疗恢复勃起”中,研究了 nightly vardenafil 与按需给药和安慰剂的疗效,结果显示在 RP 后勃起功能恢复方面没有差异。从康复的角度来看,尽管海绵体内注射被广泛应用且具有吸引力,但它的作用仍缺乏明确的证据支持。在 RP 后使用真空勃起装置的情况已有报道,但尚无数据支持其作为单一疗法的作用。也有研究报告了经尿道前列地尔与西地那非的比较,未发现前者具有优越性。
目前,我们无法确定在策略利用、干预时机或治疗持续时间方面,哪种方案是最佳康复方案。